Eucure Biopharma Announces Breakthrough Phase I Results for An...
- Written by LATEST ASIANET NEWS RELEASES
- Published in Asia Net
BOSTON and BEIJING, March 23, 2021 /PRNewswire-AsiaNet/ -- Eucure Biopharma, a subsidiary of Biocytogen focused on developing proprietary immuno-oncology antibodies, announced that its anti-CTLA-4 antibody (YH001), in combination with Junshi Biosciences' anti-PD-1 monoclonal antibody, Toripalimab Injectio...
Authors: LATEST ASIANET NEWS RELEASES